Nothing Special   »   [go: up one dir, main page]

GB0802128D0 - Therapeutic compounds and their use - Google Patents

Therapeutic compounds and their use

Info

Publication number
GB0802128D0
GB0802128D0 GBGB0802128.9A GB0802128A GB0802128D0 GB 0802128 D0 GB0802128 D0 GB 0802128D0 GB 0802128 A GB0802128 A GB 0802128A GB 0802128 D0 GB0802128 D0 GB 0802128D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic compounds
therapeutic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0802128.9A
Other versions
GB2458259A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Priority to GB0802128A priority Critical patent/GB2458259A/en
Publication of GB0802128D0 publication Critical patent/GB0802128D0/en
Publication of GB2458259A publication Critical patent/GB2458259A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0802128A 2008-02-05 2008-02-05 Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives Withdrawn GB2458259A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0802128A GB2458259A (en) 2008-02-05 2008-02-05 Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0802128A GB2458259A (en) 2008-02-05 2008-02-05 Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives

Publications (2)

Publication Number Publication Date
GB0802128D0 true GB0802128D0 (en) 2008-03-12
GB2458259A GB2458259A (en) 2009-09-16

Family

ID=39204286

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0802128A Withdrawn GB2458259A (en) 2008-02-05 2008-02-05 Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives

Country Status (1)

Country Link
GB (1) GB2458259A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081822A1 (en) * 2013-12-02 2015-06-11 北京键凯科技有限公司 3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof
CN107530430A (en) * 2015-01-13 2018-01-02 国立大学法人京都大学 For preventing and/or treating the medicament of amyotrophic lateral sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
US5854285A (en) * 1997-04-03 1998-12-29 Natpro, Inc. Protein kinase inhibitor
WO2003092693A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
WO2005049009A1 (en) * 2003-11-21 2005-06-02 The University Of Newcastle Research Associates Limited Methods and agents for inhibiting dynamin-dependent endocytosis
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
JP2008013446A (en) * 2006-07-03 2008-01-24 Neugen Pharma:Kk Treating or preventing agent of intractable disease having cell degeneration caused by oxidation stress as molecular background

Also Published As

Publication number Publication date
GB2458259A (en) 2009-09-16

Similar Documents

Publication Publication Date Title
IL249941A0 (en) Spiro-oxindole compounds and their use as therapeutic agents
GB0803018D0 (en) Therapeutic compounds and their use
GB0719803D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
GB0818241D0 (en) Compounds and their use
EP2300011A4 (en) Therapeutic methods and compounds
GB0724251D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
GB0817207D0 (en) therapeutic apsac compounds and their use
GB0817208D0 (en) Therapeutic apsap compounds and their use
EP2268281A4 (en) Thienopyrroles and pyrrolothiazoles as new therapeutic agents
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0812913D0 (en) Therapeutic compounds and their use
EP2231163A4 (en) Compounds and therapeutic use thereof
GB0801319D0 (en) Compounds and their use
GB0802128D0 (en) Therapeutic compounds and their use
GB0808690D0 (en) Therapeutic use
GB0815134D0 (en) Therapeutic compounds and their use
GB0705517D0 (en) Therapeutic compounds and their use
GB0821539D0 (en) Therapeutic compounds and their use
GB0913300D0 (en) Therapeutic compounds and their use
GB0800487D0 (en) Therapeutic use
GB0800489D0 (en) Therapeutic use

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)